Titan Pharmaceuticals
From Wikipedia, the free encyclopedia
 |
This article does not cite any references or sources. (December 2006) Please help improve this article by adding citations to reliable sources. Unverifiable material may be challenged and removed. |
 |
This article is orphaned as few or no other articles link to it. Please help introduce links in articles on related topics. (December 2006) |
 |
The introduction to this article provides insufficient context for those unfamiliar with the subject. Please help improve the article with a good introductory style. |
Titan Pharmaceuticals, Inc. is a California biopharmaceutical company.
It develops proprietary therapeutics for the treatment of central nervous system disorders, cardiovascular disease, bone disease, and other disorders primarily in the United States. Its products include Probuphine, a Phase III in preparation product, which is used for the treatment of opioid dependence; Iloperidone, a Phase III product, which is used for the treatment of schizophrenia and related psychotic disorders; and Spheramine, a Phase IIb product, which is used for the treatment of advanced Parkinson’s disease. The company’s products also includes DITPA, a Phase II product, for the treatment of congestive heart failure and hyperlipidemia; and Gallium maltolate, a Phase I product, which is used for the treatment of bone related diseases, chronic bacterial infections, and cancer. It has strategic alliance with Schering AG for the development of Spheramine and Vanda Pharmaceuticals, Inc. for the development of Iloperidone. Titan Pharmaceuticals was founded by Louis R. Bucalo.
The company was incorporated in 1992 and is based in South San Francisco, California.
This United States corporation or company article is a stub. You can help Wikipedia by expanding it.
